Infectious Disease Therapeutics Market By Product Type (Antiviral Drugs, Antibacterial Drugs, Antifungal and Antiparasitic Drugs, Monoclonal Antibodies and Immunotherapies); By Indication (HIV/AIDS, Hepatitis, Influenza, Tuberculosis, Malaria, Others); By Route of Administration (Oral, Parenteral, Topical); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Infectious Disease Therapeutics Market is projected at 7.4% CAGR, rising from $145.6 billion in 2024 to $322.5 billion by 2030, supported by biologics, antivirals, antibiotics, immune-modulating agents, and combination therapies, as per Strategic Market Research.

 

Infectious disease therapeutics encompasses pharmaceuticals, biological agents, and advanced treatment modalities developed to prevent, control, or cure infectious conditions caused by bacteria, viruses, fungi, and parasites. This market’s strategic relevance has intensified between 2024–2030 , driven by the surge in antimicrobial resistance, evolving viral epidemics, and renewed global funding for pandemic preparedness.

 

The need for novel anti-infective agents has become critical amid rising treatment failures associated with legacy antibiotics. At the same time, viral pathogens such as influenza, HIV, hepatitis, respiratory syncytial virus (RSV), and emerging coronaviruses continue to strain health systems worldwide. Regulatory bodies are fast-tracking the approval of monoclonal antibodies and novel antivirals, a trend expected to reshape the therapeutic landscape by 2030.

 

Technological innovation is also driving this market forward. Next-generation sequencing and AI-enabled drug discovery platforms are significantly reducing time-to-market for novel therapies. In parallel, combination regimens and personalized approaches are gaining traction in treating chronic infections such as HIV and hepatitis C.

 

Macroeconomic forces shaping this market include:

• Growing global disease burden : Over 1.3 billion infections annually are reported worldwide, underscoring the need for effective therapeutic interventions.

• Regulatory reforms and fast-track approvals : Agencies like the FDA and EMA are introducing accelerated pathways for high-priority infectious disease treatments.

• Expanded public-private partnerships : Organizations such as CEPI, Gavi, and BARDA have committed significant funding toward vaccine and therapeutic development.

• Increasing investments in low- and middle-income countries (LMICs) : Rising healthcare infrastructure investments are expanding treatment access.

 

Key stakeholders in this market include:

• Original Equipment Manufacturers (OEMs) : Companies developing manufacturing platforms for biologics and injectables.

• Pharmaceutical and Biotechnology Firms : Leaders driving new molecular entity discovery.

• Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) supporting accelerated development.

• Government Health Agencies and Global Health NGOs funding procurement programs.

• Hospitals and Specialized Treatment Centers that serve as primary end users.

• Investors and Venture Capitalists financing pipeline innovations.

As global infectious disease dynamics grow more complex, the therapeutic market is emerging as a critical pillar of public health resilience and economic security.

 

Comprehensive Market Snapshot

• The Global Infectious Disease Therapeutics Market is projected to grow at a 7.4% CAGR, rising from $145.6 billion in 2024 to $322.5 billion by 2030.

• The USA Infectious Disease Therapeutics Market will register a healthy 7.2% CAGR, expanding from $43.7 billion in 2024 to approximately $66.4 billion by 2030, supported by strong drug innovation pipelines, high treatment adoption, and robust reimbursement frameworks. The USA accounts for 30% of the global market in 2024.

• The Europe Infectious Disease Therapeutics Market will grow at a 6.3% CAGR, expanding from $34.9 billion in 2024 to approximately $50.3 billion by 2030, driven by expanding antimicrobial stewardship programs, rising hospital-based infection management, and sustained public healthcare spending. Europe represents 24% of the global market share.

• The APAC Infectious Disease Therapeutics Market is expected to grow at the fastest pace, registering a 9.6% CAGR, expanding from $29.1 billion in 2024 to approximately $50.4 billion by 2030, fueled by large patient populations, improving healthcare access, rising infectious disease burden, and increased government investment. APAC accounts for 20% of the global market in 2024.

 

Market Segmentation Insights

By Product Type

• Antiviral Drugs held the largest market share of approximately 38% in 2024, reflecting sustained demand for HIV, hepatitis, influenza, and emerging viral infection therapies, with an estimated market value of around USD 55.3 billion.

• Antibacterial Drugs accounted for about 34% share in 2024, valued at approximately USD 49.5 billion, driven by hospital-based infection management, surgical prophylaxis, and treatment of resistant bacterial strains.

• Antifungal and Antiparasitic Drugs represented roughly 18% of the market in 2024, translating to an estimated value of around USD 26.2 billion, supported by endemic fungal infections, malaria control programs, and neglected tropical disease treatment initiatives.

• Monoclonal Antibodies and Immunotherapies captured approximately 10% share in 2024, valued at around USD 14.6 billion, and are projected to grow at a strong CAGR during 2024–2030, driven by targeted mechanisms, severe infection management, and pipeline expansion.

 

By Indication

• HIV/AIDS represented the highest indication share of approximately 21% in 2024, supported by lifelong therapy requirements and broad global access programs, corresponding to a market value of around USD 30.6 billion.

• Hepatitis (B & C) accounted for about 19% of the market in 2024, translating to an estimated value of approximately USD 27.7 billion, driven by curative hepatitis C regimens and chronic hepatitis B treatment expansion.

• Influenza therapies captured around 15% share in 2024, with a market value of about USD 21.8 billion, supported by seasonal outbreaks and government-led antiviral stockpiling.

• Tuberculosis treatments held approximately 13% of the market in 2024, valued at around USD 18.9 billion, reflecting sustained burden in emerging economies and long-duration treatment protocols.

• Respiratory Syncytial Virus (RSV) accounted for nearly 7% share in 2024, translating to an estimated value of approximately USD 10.2 billion, and is expected to grow at a notable CAGR through 2030 due to vaccine-linked and monoclonal antibody adoption.

• Malaria and Other Bacterial & Fungal Infections collectively represented about 25% of the global market in 2024, with an estimated value of approximately USD 36.4 billion.

 

By Distribution Channel

• Hospital Pharmacies dominated distribution with around 44% market share in 2024, reflecting inpatient treatment protocols, biologic drug handling, and centralized procurement, equivalent to approximately USD 64.1 billion.

• Retail Pharmacies accounted for about 36% of the global market in 2024, translating to an estimated value of around USD 52.4 billion, supported by chronic antiviral dispensing and outpatient antibiotic therapy.

• Online Pharmacies captured approximately 20% share in 2024, valued at around USD 29.1 billion, and are forecast to grow at the highest CAGR during 2024–2030, driven by chronic therapy refills, digital prescriptions, and home delivery adoption.

 

Strategic Questions Driving the Next Phase of the Global Infectious Disease Therapeutics Market

1. What products, therapeutic classes, and pathogen targets are explicitly included within the infectious disease therapeutics market, and which interventions remain outside the defined scope?

2. How does the infectious disease therapeutics market differ structurally from adjacent vaccine, diagnostics, immunology, and preventive healthcare markets?

3. What is the current and forecasted size of the global infectious disease therapeutics market, and how is value distributed across major drug classes and disease categories?

4. How is revenue allocated between antivirals, antibacterials, antifungals, antiparasitics, and biologic therapies, and how is this mix expected to evolve through 2030?

5. Which disease segments (e.g., HIV, hepatitis, tuberculosis, respiratory viral infections, hospital-acquired infections) account for the largest and fastest-growing revenue pools?

6. Which therapeutic segments generate disproportionate value and margins relative to patient volumes and treatment intensity?

7. How does demand differ across acute, chronic, and recurrent infectious disease populations, and how does this influence treatment selection and duration?

8. How are first-line, second-line, and salvage therapies evolving across key infectious disease treatment pathways?

9. What role do treatment duration, resistance development, switching patterns, and long-term patient retention play in sustaining segment-level revenue growth?

10. How are disease prevalence, diagnosis rates, surveillance programs, and access to infectious disease care shaping market demand across regions?

11. What clinical, regulatory, resistance-related, or adherence barriers limit penetration in specific drug classes or disease indications?

12. How do pricing pressures, antimicrobial stewardship policies, reimbursement frameworks, and payer controls influence revenue realization across therapy segments?

13. How robust is the current and mid-term development pipeline, and which emerging mechanisms of action are expected to form new therapeutic categories?

14. To what extent will pipeline innovation expand the treated patient population versus intensify competition within established disease segments?

15. How are formulation innovations, combination therapies, and drug-delivery technologies improving efficacy, safety, and patient adherence?

16. How will patent expirations and loss of exclusivity reshape competition across antivirals, antibacterials, and biologic infectious disease therapies?

17. What role will generics, biosimilars, and alternative treatment regimens play in price erosion, access expansion, and volume growth?

18. How are leading pharmaceutical companies aligning disease-specific portfolios, partnerships, and commercialization strategies to defend or grow market share?

19. Which geographic regions are expected to outperform global growth in the infectious disease therapeutics market, and which disease segments are driving this outperformance?

20. How should manufacturers, investors, and policymakers prioritize specific disease areas, therapeutic platforms, and regions to maximize long-term value creation?

 

Segment-Level Insights and Market Structure 

The Infectious Disease Therapeutics Market is organized around diverse drug classes and delivery channels that reflect variation in pathogen type, disease duration, resistance risk, and care settings. Each segment plays a distinct role in shaping market value, competitive intensity, and long-term growth potential, influenced by epidemiological patterns, treatment guidelines, and healthcare system capacity.

 

Product Type Insights

Antiviral Drugs

Antiviral therapies form the backbone of the infectious disease therapeutics market, particularly in chronic and high-burden indications such as HIV, hepatitis B and C, and seasonal or emerging respiratory viruses. Their widespread use is driven by long treatment durations, global access programs, and strong public health prioritization. From a commercial perspective, antivirals generate recurring revenue streams and stable demand, especially in markets with well-established screening and diagnosis frameworks. Over time, this segment is evolving toward fixed-dose combinations and resistance-resilient formulations.

Antibacterial Drugs

Antibacterial therapies remain essential for managing acute infections, hospital-acquired infections, and surgical prophylaxis. Their clinical importance spans both community and institutional settings, with usage patterns heavily influenced by resistance trends and stewardship policies. While treatment durations are typically short, the segment commands significant volume due to the breadth of bacterial pathogens. Market dynamics within antibacterials are increasingly shaped by innovation focused on resistant strains and by regulatory incentives aimed at revitalizing antibiotic development.

Antifungal and Antiparasitic Drugs

This segment addresses systemic and localized fungal infections, malaria, and other parasitic diseases, particularly in immunocompromised populations and endemic regions. Demand is closely tied to regional disease prevalence and public health intervention programs. Although narrower in scope compared to antivirals and antibacterials, antifungal and antiparasitic therapies occupy a strategically important position due to limited therapeutic alternatives and the severity of untreated infections.

Biologics and Immunotherapy-Based Treatments

Biologic therapies, including monoclonal antibodies and immune-modulating agents, represent a high-value, innovation-driven segment within the market. These therapies are increasingly used in severe, high-risk, or treatment-resistant infections, particularly where rapid pathogen neutralization or immune enhancement is required. Adoption is more selective due to cost, administration complexity, and infrastructure requirements, but continued clinical development is expected to expand their role, especially in emerging viral threats and combination regimens.

 

Segment Evolution Perspective

Established small-molecule therapies continue to anchor current treatment practices across most infectious diseases. However, biologics, combination regimens, and resistance-focused innovation are gradually reshaping the therapeutic mix. At the same time, distribution channels are evolving in response to shifts toward outpatient care, oral therapies, and digital fulfillment models. Collectively, these dynamics are expected to redefine how value, competition, and innovation are distributed across the infectious disease therapeutics market over the forecast period.

 

Market Segmentation And Forecast Scope

The infectious disease therapeutics market can be segmented across multiple dimensions to reflect the diversity of therapeutic approaches and target indications. For clarity and actionable insight, this research defines the segmentation as follows:

By Product Type

• Antiviral Drugs: Therapies targeting viral pathogens such as HIV, hepatitis viruses, influenza, and emerging coronaviruses.

• Antibacterial Drugs: Including broad-spectrum antibiotics and narrow-spectrum agents addressing resistant bacterial strains.

• Antifungal and Antiparasitic Drugs: Therapeutics for systemic and localized fungal infections, malaria, and neglected tropical diseases.

• Monoclonal Antibodies and Immunotherapies: Advanced biologics with targeted mechanisms of action.

In 2024, the antiviral drugs segment alone accounts for approximately 38% of total revenue, underscoring the persistent burden of viral infections and global antiviral stockpiling.

 

By Indication

• HIV/AIDS

• Hepatitis (B & C)

• Influenza

• Respiratory Syncytial Virus (RSV)

• Tuberculosis

• Malaria

• Other Bacterial and Fungal Infections

Among these, Hepatitis C therapies represent one of the fastest-growing segments due to curative treatment innovations and expanded screening initiatives.

 

By Route of Administration

• Oral (tablets, capsules)

• Parenteral (injectables, infusions)

• Topical

 

By Distribution Channel

• Hospital Pharmacies : Primary centers for acute and chronic infection management.

• Retail Pharmacies : Dispensing maintenance antivirals and antibiotics.

• Online Pharmacies : Gaining share for chronic therapy refills.

 

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

In 2024, North America leads the market in revenue terms, driven by advanced healthcare infrastructure, reimbursement support, and high per capita drug spending. However, Asia Pacific is expected to register the fastest CAGR through 2030, propelled by expanding access programs and rising infection incidence.

Forecast Scope This research quantifies revenue and growth trends across all regions and product segments, with particular focus on:

• The transition from small-molecule antivirals to biologics.

• Pipeline impact from next-generation monoclonal antibodies.

• Evolving reimbursement policies influencing adoption rates.

By 2030, combination regimens integrating immunotherapy and antiviral drugs are projected to account for a substantial share of treatment protocols, reflecting a strategic pivot toward multi-mechanism approaches.

 

Market Trends And Innovation Landscape

The infectious disease therapeutics market is undergoing a transformative phase marked by unprecedented R&D momentum, cross-sector collaborations, and technological breakthroughs. Several prominent innovation trends are defining the competitive trajectory between 2024 and 2030 :

Advances in Drug Discovery and AI Integration

• Artificial intelligence and machine learning platforms are accelerating compound screening and target validation. By leveraging AI models trained on pathogen genomics, researchers can now identify viable antiviral candidates in weeks instead of months.

• Predictive algorithms are enabling the design of precision antibiotics capable of circumventing resistance mechanisms, especially for multidrug-resistant Gram-negative bacteria.

 

Rise of Monoclonal Antibodies and Immunotherapies

• Monoclonal antibody treatments have gained traction as targeted interventions for viral infections, including RSV and Ebola.

• In the coming years, combination regimens blending traditional antivirals with immunomodulatory therapies are expected to redefine standard-of-care protocols.

 

Pipeline Expansion and Diversification

• The global pipeline includes over 550 active compounds , ranging from nucleotide analogs to therapeutic vaccines.

• Companies are increasingly prioritizing dual-action molecules—agents that possess both antiviral and immunostimulatory properties—to address emerging infections and endemic diseases.

 

Innovative Drug Delivery Systems

• Long-acting injectables and depot formulations are under development to improve adherence, especially in chronic infections like HIV.

• Nanoparticle-based delivery platforms are enhancing bioavailability and targeted tissue distribution, reducing systemic toxicity.

 

Strategic Partnerships and Collaborative Ecosystems

• Recent years have seen a surge in public-private alliances. For example, multi-stakeholder initiatives are pooling resources to develop pandemic readiness platforms.

• Consortia combining big pharma, academic institutions, and NGOs are accelerating late-stage clinical trials for next-generation antibiotics and antivirals.

 

Select Illustrative Developments

• The development of pan-influenza antivirals capable of covering multiple strains.

• The scaling of oral COVID-19 antivirals for seasonal preparedness.

• The refinement of rapid diagnostic-linked therapies to enable point-of-care treatment initiation.

According to expert commentary, these trends will fundamentally shift the market from reactive treatment toward proactive, personalized infection management: “The future of infectious disease therapeutics lies at the intersection of rapid pathogen identification and targeted, adaptive therapy that evolves in parallel with microbial threats.”

 

Competitive Intelligence And Benchmarking

The infectious disease therapeutics market is characterized by a highly dynamic competitive landscape where established pharmaceutical leaders and innovative biotechnology firms are vying to advance differentiated therapies. Below are seven prominent companies , each contributing distinctive strengths and strategic approaches:

Gilead Sciences

• A global pioneer in antiviral drug development, Gilead’s strategy centers on maintaining leadership in HIV and hepatitis therapeutics.

• The company leverages a robust pipeline of combination antivirals and invests heavily in lifecycle management to extend product viability.

• Its global reach extends across North America, Europe, and Asia Pacific, supported by comprehensive distribution and patient assistance programs.

 

GlaxoSmithKline

• GSK combines an extensive antibacterial and antiviral portfolio with emerging vaccine adjacencies.

• The firm emphasizes R&D partnerships to accelerate new molecules targeting resistant infections.

• Its broad geographic presence and historical expertise in infectious disease franchises make it a trusted supplier to health systems and NGOs.

 

Merck & Co.

• Merck is strengthening its position through novel antiviral candidates and immunotherapies.

• A significant portion of its infectious disease revenue comes from vaccines, which complement therapeutic offerings.

• The company’s global clinical trial network allows for rapid pivoting toward emerging outbreaks.

 

Pfizer

• Pfizer has expanded aggressively into infectious disease therapeutics beyond vaccines, focusing on oral antivirals and monoclonal antibody solutions.

• Its recent investments in manufacturing infrastructure have enabled scale-up capabilities for rapid deployment.

• Strategic alliances are core to Pfizer’s approach, enhancing its pipeline diversification.

 

Roche

• Roche focuses on diagnostics-integrated therapeutics, particularly in influenza and hepatitis.

• The company differentiates itself through companion diagnostics that optimize treatment timing and patient selection.

• Roche’s European stronghold is complemented by growing market share in Asia Pacific.

 

Johnson & Johnson

• J&J leverages its Janssen unit to drive innovation in HIV treatment and multidrug-resistant tuberculosis.

• The firm’s strategy combines small molecules with investigational long-acting injectable formulations.

• Its global reach is supported by partnerships with NGOs and public health agencies.

 

AbbVie

• AbbVie holds a strong position in hepatitis C therapeutics and is investing in next-generation antiviral combinations.

• It continues to pursue biologics for difficult-to-treat infections, differentiating its pipeline from traditional small molecules.

• AbbVie’s North American revenue base is balanced by aggressive expansion into emerging markets.

These companies collectively set the benchmark for R&D intensity, supply chain agility, and pricing strategies that are reshaping competitive dynamics. The emergence of smaller biotech firms specializing in monoclonal antibodies and RNA-based therapeutics is expected to further intensify competition.

 

Regional Landscape And Adoption Outlook

The infectious disease therapeutics market exhibits pronounced regional differences in adoption rates, regulatory frameworks, and infrastructure capacity. Understanding these dynamics is crucial for identifying growth hotspots and unmet needs:

North America

• The region maintains the largest share, driven by sophisticated healthcare infrastructure, strong reimbursement policies, and a high incidence of chronic viral infections.

• The United States leads global demand for HIV and hepatitis therapeutics. Regulatory initiatives, such as the FDA’s accelerated approval pathways, continue to encourage rapid commercialization of innovative therapies.

• Canada’s market is shaped by centralized procurement and funding models that favor cost-effective generics alongside novel treatments.

 

Europe

• Europe is a mature market with robust regulatory frameworks and an increasing emphasis on antimicrobial stewardship.

• Countries such as Germany, France, and the UK are front-runners in adopting combination therapies and diagnostics-linked treatment pathways.

• Pan-European initiatives are expanding stockpiles for pandemic preparedness, including RSV and influenza antivirals.

• Regulatory harmonization under EMA guidelines ensures consistent quality standards but can introduce delays for niche therapies seeking reimbursement approval.

 

Asia Pacific

• Asia Pacific is expected to deliver the fastest CAGR through 2030, supported by rising infection rates, improving healthcare access, and government-led treatment initiatives.

• China and India represent the largest addressable patient populations, especially in hepatitis B and tuberculosis.

• Japan and South Korea demonstrate high uptake of innovative antivirals and diagnostics-driven care models.

• The region remains a key focus for multinational pharmaceutical firms investing in local manufacturing and technology transfer agreements.

 

Latin America

• Latin America’s market growth is spurred by public health investments targeting endemic infections and improved diagnostic infrastructure.

• Brazil leads in adoption of HIV and hepatitis C therapies, supported by government-funded treatment programs.

• However, reimbursement challenges and variable regulatory timelines can slow market entry.

 

Middle East & Africa

• The region faces a disproportionate burden of infectious diseases such as HIV, tuberculosis, and malaria.

• Limited healthcare infrastructure and funding constraints impede access to next-generation therapies.

• International donor funding and NGO-led procurement play a critical role in maintaining therapeutic supply chains.

• Countries like South Africa are progressively adopting integrated care models, blending prevention, diagnostics, and treatment.

 

White Space and Underserved Areas

• Rural and peri-urban regions across Africa and Southeast Asia continue to experience treatment gaps.

• Low diagnostic capacity and weak cold chain infrastructure hinder uptake of biologics and temperature-sensitive antivirals.

• These underserved markets represent significant opportunities for partnerships, technology transfer, and scalable solutions tailored to resource-limited settings.

Regional diversity in disease prevalence, healthcare policy, and payer ecosystems makes a localized strategy essential for market success.

 

End-User Dynamics And Use Case

The infectious disease therapeutics market serves a complex matrix of end users, each with unique treatment protocols, procurement practices, and decision-making criteria. Understanding these dynamics is essential for aligning go-to-market strategies with operational realities.

Hospitals and Tertiary Care Centers

• These institutions are the primary end users of advanced infectious disease therapeutics, including injectables, biologics, and combination regimens.

• Hospitals often operate within centralized formulary systems that evaluate cost-benefit profiles and clinical outcomes before adoption.

• In high-income countries, hospital protocols increasingly incorporate diagnostics-driven decision trees to optimize therapy selection.

 

Specialized Infectious Disease Clinics

• Clinics focused on HIV, hepatitis, and tuberculosis play a crucial role in ongoing patient management.

• They emphasize long-term adherence strategies and are early adopters of innovative oral antivirals and long-acting injectables.

 

Retail and Community Pharmacies

• Community pharmacies are integral to dispensing maintenance therapies for chronic viral infections.

• Their role is expanding as telehealth and online prescribing platforms drive direct-to-patient fulfillment models.

 

Government and NGO Health Programs

• Public health agencies procure and distribute large volumes of standard-of-care treatments, particularly in low- and middle-income countries.

• NGOs often collaborate with local governments to implement treatment campaigns targeting endemic diseases such as malaria and tuberculosis.

 

Research Institutes and Academic Centers

• These end users are heavily engaged in clinical trials for investigational agents and combination regimens.

• They serve as early access points for innovative treatments before commercial roll-out.

 

Use Case Example A tertiary hospital in Seoul, South Korea, integrated an AI-enabled rapid diagnostic platform with its infectious disease unit. By pairing this system with a new-generation combination antiviral therapy for hepatitis C, clinicians achieved a 35% reduction in treatment initiation time and a 20% improvement in sustained virologic response rates. This integration showcased how diagnostic precision and therapeutic innovation can converge to improve patient outcomes and operational efficiency.

End-user engagement is evolving rapidly as new technologies and care models reshape traditional treatment pathways. Companies that invest in education, diagnostics integration, and adherence support will be best positioned to capture share.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• In 2023, Pfizer announced the launch of an oral antiviral targeting seasonal coronaviruses, designed for outpatient treatment.

• Gilead Sciences expanded its global access program to include next-generation HIV combination therapies across 90 low-income countries.

• Merck & Co. received approval for a long-acting injectable formulation to treat multidrug-resistant tuberculosis.

• In 2024, GlaxoSmithKline entered a strategic collaboration with a leading AI platform to accelerate antibacterial candidate discovery.

• AbbVie initiated a Phase III trial evaluating a combination antiviral-immunotherapy regimen for chronic hepatitis B.

 

Opportunities

• Expansion in Emerging Markets Rapid improvements in healthcare access in Asia Pacific and Sub-Saharan Africa are unlocking significant demand for innovative therapies.

• Integration of AI and Genomics Advanced analytics and genomics platforms are enabling precision therapeutics and faster time-to-market.

• Growth in Long-Acting Formulations Depot injections and implants are expected to improve adherence in chronic infection management.

 

Restraints

• Regulatory Complexity and Delays Diverse approval pathways across regions can slow market entry for novel therapeutics.

• High Development and Manufacturing Costs Biologics and advanced delivery systems require substantial investment, impacting pricing and access.

These developments and constraints will continue to shape both strategic priorities and competitive pressures through 2030.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 145.6 Billion
Revenue Forecast in 2030	USD 322.5 Billion
Overall Growth Rate	CAGR of 7.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Indication, By Route of Administration, By Distribution Channel, By Geography
By Product Type	Antiviral Drugs, Antibacterial Drugs, Antifungal and Antiparasitic Drugs, Monoclonal Antibodies and Immunotherapies
By Indication	HIV/AIDS, Hepatitis, Influenza, Tuberculosis, Malaria, Others
By Route of Administration	Oral, Parenteral, Topical
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, South Africa
Market Drivers	- Rising global infectious disease burden - Innovation in antiviral and monoclonal antibody development - Expansion of treatment access in emerging economies
Customization Option	Available upon request